|Dr. Neil Kumar||Co-Founder, CEO & Director||897.57k||N/A||1980|
|Dr. Charles J. Homcy||Chairman of Pharmaceuticals & Lead Director||735.54k||N/A||1948|
|Dr. Richard H. Scheller||Chairman of R&D and Director||N/A||N/A||1953|
|Dr. Brian C. Stephenson C.F.A., Ph.D.||CFO, Sec. & Principal Accounting Officer||N/A||N/A||1981|
|Ms. Yi Ching Yau||Chief Accounting Officer||N/A||N/A||N/A|
|Dr. Uma Sinha||Chief Scientific Officer||N/A||N/A||1958|
|Dr. Frank McCormick Ph.D.||Chairman of Oncology||N/A||N/A||1950|
|Dr. Michael Thomas Henderson M.D.||Chief Bus. Officer||N/A||N/A||1990|
|Dr. Cameron Turtle DPHIL, Ph.D.||Chief Strategy Officer||N/A||N/A||1990|
|Mr. Eli M. Wallace||Chief Scientific Officer of Residence - Oncology Programs||N/A||N/A||1967|
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include BBP-265, a small molecule stabilizer of transthyretin, or TTR, that is in an ongoing Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor which is an ongoing Phase 2 clinical trial for the treatment of achondroplasia in pediatric patients; an AAV5 gene transfer product candidate for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD; and Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, an ongoing phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1. The company also engages in developing products for Mendelian, genetic dermatology, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; The Regents of the University of California; Leidos Biomedical Research, Inc.; the University of California, San Diego; Johns Hopkins University and University of Florida; University of Colorado Anschutz Medical Campus; Salk Institute for Biological Studies; Maze Therapeutics; UC San Francisco; the Canadian Glycomics Network (GlycoNet); and the University of California, Davis. The company was founded in 2015 and is headquartered in Palo Alto, California.
BridgeBio Pharma, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 9. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 6; Compensation: 9.